Brief: Fibrobiologics Receives Hrec Approval For Phase 1/2 Clinical Trial For Cywc628 For The Treatment Of Refractory Diabetic Foot Ulcers
20/11/2025 13:12
Fibrobiologics Inc FBLG.O: FIBROBIOLOGICS RECEIVES HREC APPROVAL FOR PHASE 1/2 CLINICAL TRIAL FOR CYWC628 FOR THE TREATMENT OF REFRACTORY DIABETIC FOOT ULCERS Source text: ID:nGNX3whfM4 Further company coverage: FBLG.O
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts